- Home
- BVN vs TWST Comparison
BVN vs TWST Comparison
Compare BVN & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BVN | TWST |
|---|---|---|
| Founded | 1953 | 2013 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 9.2B |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BVN | TWST |
|---|---|---|
| Price | $34.86 | $165.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $44.00 | ★ $46.88 |
| AVG Volume (30 Days) | 904.2K | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.78% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | $29.99 | $18.91 |
| Revenue Next Year | N/A | $15.07 |
| P/E Ratio | $21.78 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $21.00 | $23.30 |
| 52 Week High | $44.67 | $170.23 |
Technical Indicators
Market Signals| Indicator | BVN | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 70.94 |
| Support Level | $32.60 | $39.81 |
| Resistance Level | $36.50 | N/A |
| Average True Range (ATR) | 1.14 | 9.27 |
| MACD | -0.14 | 2.71 |
| Stochastic Oscillator | 41.87 | 89.25 |
Price Performance
Historical ComparisonAbout BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.